GlassScriptPhysician profile
Joseph Saba
NPI 1639109424
$4,849.20
in general payments reported to CMS, 2019-2025
31 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $1,000 · 2021: $1,053 · 2022: $1,186 · 2023: $676 · 2024: $319 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $670.51 | 2020-2023 | |
| Supernus Pharmaceuticals, INC. | $649.28 | 2019-2022 | |
| Abbvie INC. | $635.61 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Amgen INC. | $326.42 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $316.50 | 2022 | |
| Avanir Pharmaceuticals, INC. | $280.32 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $265.28 | 2021 | |
| Pfizer INC. | $230.80 | 2023-2025 | |
| Allergan, INC. | $212.71 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $197.77 | 2019-2024 | Ajovy, Austedo |
| Ucb, INC. | $186.75 | 2019-2023 | Briviact |
| Eisai INC. | $100.46 | 2023-2025 | |
| Lilly USA, LLC | $94.28 | 2022-2024 | Kisunla, Emgality, Reyvow |
| Emd Serono, INC. | $74.67 | 2021-2022 | |
| Sk Life Science, INC. | $73.68 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $62.70 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $58.29 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $57.72 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $53.17 | 2020-2021 | |
| Lundbeck LLC | $44.02 | 2022-2023 | Vyepti |
| Corium, LLC | $34.15 | 2023 | Adlarity |
| Arbor Pharmaceuticals, INC. | $32.72 | 2020-2022 | |
| Biogen, INC. | $31.42 | 2021 | |
| Kyowa Kirin, INC. | $31.01 | 2020-2021 | |
| Grt US Holding, INC. | $25.32 | 2022 | |
| Adamas Pharmaceuticals, INC. | $21.73 | 2020 | |
| Argenx US, INC. | $20.98 | 2024 | Vyvgart Hytrulo |
| Genzyme Corporation | $19.04 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.98 | 2022 | |
| Livanova USA, INC. | $12.40 | 2021 | |
| Greenwich Biosciences, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Saba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.